Europese Unie - Engels - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5n2 subtype (strain a/duck/potsdam/1402/86) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.efficacy has been evaluated on the basis of preliminary results in chickens. reduction of clinical signs, mortality and excretion of virus after challenge were shown by three weeks after vaccination.serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.

Europese Unie - Engels - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5 subtype (strain h5n6, a/duck/potsdam/2243/84) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.reduction of clinical signs, mortality and excretion of virus after challenge with a virulent h5n1 strain, were shown by two weeks after a single dose vaccination.serum antibodies have been shown to persist in chickens for at least 7 months and studies performed with other vaccine strains show that serum antibodies would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine.

Europese Unie - Engels - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h7n1 subtype (strain, a/ck/italy/473/99) - immunologicals for aves - chicken; ducks - for active immunisation of chickens and ducks against avian influenza type a, subtype h7n1.efficacy has been evaluated on the basis of preliminary results in chickens and ringed teals.in chickens, reduction of clinical signs, mortality, excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.in ducks, reduction of excretion and transmission of virus after challenge were shown by two weeks after a single dose vaccination.although it has not been investigated with this particular ai vaccine strain, studies performed with other strains show that protective levels of serum antibody titres would be expected to persist in chickens for at least 12 months after administration of two doses of vaccine. the duration of immunity in ducks is unknown.

Europese Unie - Engels - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

Europese Unie - Engels - EMA (European Medicines Agency)

seqirus gmbh - influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain(a/brisbane/10/2010, wild type)a/switzerland/9715293/2013 (h3n2) - like strain(a/south australia/55/2014, wild type)b/phuket/3073/2013–like strain(b/utah/9/2014, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza for adults, especially in those who run an increased risk of associated complications.optaflu should be used in accordance to official guidance.

Verenigde Staten - Engels - NLM (National Library of Medicine)

medimmune, llc - influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen (unii: fv9fgc9yzw) (influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen - unii:fv9fgc9yzw), influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen (unii: l7z42hp5rz) (influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen - unii:l7z42hp5rz), influenza b virus b/austria/1359417/2021 live (attenuated) antigen (unii: jv6nd6vmy5) (influenza b virus b/austria/1359417/2021 live (attenuated) - influenza a virus a/slovenia/2903/2015 (h1n1) live (attenuated) antigen 10000000 [ffu] in 0.2 ml - flumist®  quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine [see description (11)] . flumist quadrivalent is approved for use in persons 2 through 49 years of age. do not administer flumist quadrivalent to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11)] including egg protein, or after a previous dose of any influenza vaccine. do not administer flumist quadrivalent to children and adolescents through 17 years of age who are receiving aspirin therapy or aspirin-containing therapy because of the association of reye’s syndrome with aspirin and wild-type influenza infection [see drug interactions (7.1)] . risk summary flumist quadrivalent is not absorbed systemically following intranasal administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations disease-ass

Verenigde Staten - Engels - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/bri - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza a virus subtypes and influenza type b virus contained in the vaccine. flublok is approved for use in persons 18 years of age and older. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see postmarketing experience [6.2] and description [11] ). pregnancy outcomes in women who have been exposed to flublok during pregnancy are being monitored. contact: protein sciences corporation by calling 1-888-855-7871. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. available data on flublok administered to pregnant women are insufficient to inform vaccine-associated risks in pregnant women. a developmental study of flublok has been performed in

Verenigde Staten - Engels - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e), influenza b virus (unii: 1314jz2x6w) (influenza b virus - unii:1314jz2x6w), measles virus (unii: ht3r7c012q) (measles virus - unii:ht3r7c012q), aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), antimony potassium tartrate (unii: dl6oz476v3) (antimony cation (3+) - unii:069647rpt5), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), arsenic trioxide (unii: s7v92p67ho) (arsenic catio - influenza a virus 30 [hp_x] in 1 ml - viral infection  formulated for symptoms associated with mumps, tuberculosis, whooping cough, influenza, measles and other viral infections. formulated for symptoms associated with mumps, tuberculosis, whooping cough, influenza, measles and other viral infections.

Verenigde Staten - Engels - NLM (National Library of Medicine)

newton laboratories, inc. - influenza a virus (unii: r9hh0nde2e) (influenza a virus - unii:r9hh0nde2e), influenza b virus (unii: 1314jz2x6w) (influenza b virus - unii:1314jz2x6w), measles virus (unii: ht3r7c012q) (measles virus - unii:ht3r7c012q), aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), antimony potassium tartrate (unii: dl6oz476v3) (antimony cation (3+) - unii:069647rpt5), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), arsenic trioxide (unii: s7v92p67ho) (arsenic catio - influenza a virus 30 [hp_x] in 1 g - viral infection  formulated for symptoms associated with mumps, tuberculosis, whooping cough, influenza, measles and other viral infections. formulated for symptoms associated with mumps, tuberculosis, whooping cough, influenza, measles and other viral infections.

Verenigde Staten - Engels - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated) (unii: au5c98u4bb) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:c46xjt9fq9), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (formaldehyde inactivated) (unii: f5qv7af326) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:n969qk7xd2), influenza b virus b/austria/1359417/2021 bvr-26 antigen - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - fluarix quadrivalent is indicated for active immunization for the prevention of disease caused by influenza a subtype viruses and type b viruses contained in the vaccine [see description (11)] . fluarix quadrivalent is approved for use in persons aged 6 months and older. do not administer fluarix quadrivalent to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous administration of any influenza vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data from a pregnancy registry do not suggest an increased risk of major birth defects and miscarriage in individuals who received fluarix quadrivalent within 28 days prior to conception or during pregnancy (see d